https://scholars.lib.ntu.edu.tw/handle/123456789/639917
標題: | RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants | 作者: | Nishino, Kazumi JIN-YUAN SHIH Nakagawa, Kazuhiko Reck, Martin Garon, Edward B Carlsen, Michelle Matsui, Tomoko Visseren-Grul, Carla Nadal, Ernest |
關鍵字: | Carcinoma; EGFR exon 19 deletion variant; Non–small cell lung; Ramucirumab; Targeted therapy; VEGFR inhibition | 公開日期: | 二月-2024 | 卷: | 5 | 期: | 2 | 來源出版物: | JTO clinical and research reports | 摘要: | EGFR gene mutations are drivers of NSCLC. The RELAY double-blind, placebo (PBO)-controlled phase 3 study revealed superior progression-free survival (PFS) for ramucirumab plus erlotinib (RAM + ERL) versus PBO (PBO + ERL) in patients with untreated advanced NSCLC and an EGFR-activating mutation. This exploratory analysis evaluated potential associations between EGFR exon 19 deletion (ex19del) variants and clinical outcomes. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/639917 | ISSN: | 26663643 | DOI: | 10.1016/j.jtocrr.2023.100624 |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。